WO2021260636A1 - A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract - Google Patents

A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract Download PDF

Info

Publication number
WO2021260636A1
WO2021260636A1 PCT/IB2021/055647 IB2021055647W WO2021260636A1 WO 2021260636 A1 WO2021260636 A1 WO 2021260636A1 IB 2021055647 W IB2021055647 W IB 2021055647W WO 2021260636 A1 WO2021260636 A1 WO 2021260636A1
Authority
WO
WIPO (PCT)
Prior art keywords
carnosine
pharmaceutical composition
derivatives
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
PCT/IB2021/055647
Other languages
French (fr)
Inventor
Shyam Sunder Singh
Original Assignee
Shyam Sunder Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shyam Sunder Singh filed Critical Shyam Sunder Singh
Publication of WO2021260636A1 publication Critical patent/WO2021260636A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • the present invention relates to a pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
  • the present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to a controlled release pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
  • Oxidative stress, ion balance and pH balance are some the most critical factors involved in the major acute and chronic physiological imbalance.
  • the depletion of powerful antioxidant renders cells particularly vulnerable to oxidative stress.
  • the resulting damage is the key step in the onset and progression of many disease states.
  • Degenerative nerve diseases relates to progressive damage to the neurons in the nervous system.
  • Several nervous disorder includes Alzheimer's disease (AD), Parkinson's disease (PD), Dementia and so on.
  • AD Alzheimer's disease
  • PD Parkinson's disease
  • Dementia Dementia
  • endogenous and exogenous compound are known to protect against oxidative stress and apoptosis. These endogenous and exogenous compound are helpful in management and prevention of degenerative nerve diseases.
  • L-Carnosine is used as protective agent for many therapies. Ginkgo Biloba extract reduces oxidative damage and stimulates cell survival. While both these compounds are known to be administrated individually for their respective mechanism of action, administration with immediate release has a limitation of multiple daily administration leading to fluctuating plasma concentrations.
  • composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one or both active ingredient are in controlled release form, are not known.
  • the present invention relates to pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
  • the present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to a controlled release pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
  • the active ingredient as per present invention are used in therapeutically effective amount.
  • “Therapeutically effective amount” or “effective amount” refers to the amount of a pharmaceutically active agent when administered, is sufficient to affect such prevention or treatment.
  • the therapeutically effective amount will vary depending on the disease and its severity, and the age, weight, and other conditions of the patient to be treated.
  • pharmaceutical compositions herein refers to any composition for administration to human or animal by any route and includes but are not limited to delayed release, extended release and pulsed-release.
  • immediate release refers to any composition for administration to human or animal which releases active ingredient upon administration immediately.
  • controlled release refers to any composition for administration to human or animal which is not immediate release and includes extended release, delayed release and pulsatile release.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
  • the present invention relates to a pharmaceutical composition consisting of a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to a controlled release pharmaceutical composition
  • a controlled release pharmaceutical composition comprising c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
  • the present invention relates to a controlled release pharmaceutical composition consisting of c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
  • the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
  • the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition is a bilayer tablet.
  • the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition comprises comprises Hydroxy Propyl Methyl cellulose as extended release polymer.
  • the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b.
  • Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition releases less than 90% L-Carnosine or pharmaceutically acceptable salts or derivatives thereof after 8 hours in 6.8 pH phosphate buffer.
  • the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in extended release form and wherein said composition is a bilayer tablet.
  • the present invention relates to a controlled release pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
  • the present invention relates to a controlled release oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
  • a pharmaceutical composition as per present invention includes delayed release, extended release, pulsatile release or combination thereof.
  • a pharmaceutical composition as per present invention comprises active ingredients in homogenous mixture or physically separated compartments.
  • a pharmaceutical composition as per present invention comprises L-Carnosine or pharmaceutically acceptable salts or derivatives thereof are in extended release form.
  • a pharmaceutical composition as per present invention includes for oral, intravenous or other routes of administration.
  • a pharmaceutical composition as per present invention includes solid, liquid, semisolid or other dosage forms.
  • the present invention also relates to a process for preparation of a pharmaceutical composition wherein said process comprises step of a. Preparing granules of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof with at least one controlled release excipient, b. Preparing granules of Ginkgo Biloba extract, c. Processing granules of step (a) and step (b) into bilayer tablet.
  • a process as per present invention involves non aqueous solvent granulation.
  • Carnosine is an endogenous dipeptide, composed of b-alanine and L- histidine. Carnosine has pH-buffering, metal-ion chelation, and antioxidant capacity as well as the capacity to protect against formation of advanced glycation and lipoxidation end-products. Carnosine is found naturally mainly in the skeletal muscles, central nervous system, olfactory neurons and in the lens of the eye in some vertebrates, including humans.
  • carnosine may be involved in the prevention and therapy of oxidative driven disorders, including neurodegenerative diseases and hypoxic-ischemic damage of CNS.
  • Carnosine treatment has been reported to improve glucose metabolism as well as spatial recognition memory, retention and recall. It has also been reported to have pronounced neuroprotective action on Parkinson’s disease increasing efficiency of basic therapy and suppressing beta amyloid peptide toxicity in Alzheimer’s disease.
  • L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in the equivalent therapeutically effective amount of L-Carnosine. In a preferred embodiment, L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in an amount equivalent to 50mg to 400mg of L-Camosine.
  • Ginkgo Biloba is the leaf extract primarily for China. It has antioxidant, anti-apoptotic, anti-ageing properties. In ancient and modem Chinese herbal pharmacopoeia, it is indicated for treatment for heart and lung complications. In US and Europe, it is used for its protective effect on neuron in de-generative dementias of the Alzheimer type. Dementia is a chronic or progressive condition characterized by impaired cognitive capacity.
  • Ginkgo Biloba Extract mainly contains 22.0 - 27.0% flavonoids, calculated as flavonoid glycosides and terpenoids, terpenoids consisting of bilobalide and the ginkgolides (2.6 - 3.2% bilobalide and 2.8 - 3.4% ginkgolides A, B and C).
  • terpenoids consisting of bilobalide and the ginkgolides (2.6 - 3.2% bilobalide and 2.8 - 3.4% ginkgolides A, B and C).
  • Usually administered doses of Ginkgo Biloba extract is 120-240 mg/day divided into 2 or 3 doses with meals. It has time to peak plasma concentration (Tmax) of 1 to 2 hours and shorter plasma half-life of ginkgolide A (3 to 4 hours) and B (4 to 6 hours) and bilobalide (2 to 3 hours) with primary excreted in the urine unchanged. Multiple daily doses lead to non-uniform plasma levels of its content in the body.
  • Ginkgo Biloba Extract is in an amount of 20 mg to 200 mg.
  • L-Carnosine is the antioxidant with neuroprotective effect through involvement in endogenous pathway.
  • Gingko biloba extract is a herbal exogenous antiapoptotic agent with directly neuroprotective effect.
  • the present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
  • the present invention relates to a controlled release pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
  • the pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Carnosine in the ratio between 1:1 and 1:6. In one embodiment, the pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Camosine in an amount of 60mg;200mg, 90mg;300mg and 120mg; 400mg.
  • the pharmaceutical compositions are the different type of medicinal preparation designed for the administration of targeted one or more drugs.
  • the pharmaceutical compositions as per present invention includes immediate release, delayed release, extended release and pulsed-release.
  • the pharmaceutical compositions can be prepared using uniform mixture of two or more drugs.
  • pharmaceutical composition can be prepared with one or more drugs in separate compartment within a single dosage form.
  • the pharmaceutical compositions as per present invention can be administered by oral, intravenous or other routes of drug administration.
  • the pharmaceutical compositions as per present invention can be solid, liquid, semisolid or any other dosage form.
  • the pharmaceutical compositions as per present invention can be prepared as one or more drug in modified release and other drugs as immediate release in single dosage form.
  • the oral pharmaceutical dosage form are tablets, capsules, suspensions, powders and granules, multi-particulate dosage forms and the likes.
  • the multicompartment dosage form are bilayer tablets, capsule-in-capsule, tablet-in capsule and any other dosage form.
  • the pharmaceutical compositions can be formulated by any techniques known to or appreciated by a person skilled in the art
  • the controlled release excipients as per present invention includes enteric polymer, sustained release polymers, natural polysaccharides, wax.
  • the representative controlled release agents are hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, polyethylene glycol, sodium alginate and so on.
  • the oral pharmaceutical composition further includes optionally any one or a combination of one or more pharmaceutically acceptable excipients, such as but not limited to carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants and solubility enhancers.
  • Each film coated bilayer tablet Contains: Ginkgo biloba 60 mg (as immediate release form) and L-Camosine 200 mg (as sustained release form)
  • Sift Crospovidone (XL- 10, Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate through 40# mesh sieve and collect into a poly bag Transfer the 20# mesh dried sifted granules into the blender and add the total sifted (40 # mesh) quantity of Crospovidone (XL- 10), Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate into the blender and mix for 15min at 10 RPM.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.

Description

A PHARMACEUTICAL COMPOSITION COMPRISING L-CARNOSINE AND GINKGO BILOBA EXTRACT.
The present invention relates to a pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
BACKGROUND OF INVENTION
Oxidative stress, ion balance and pH balance are some the most critical factors involved in the major acute and chronic physiological imbalance. The depletion of powerful antioxidant renders cells particularly vulnerable to oxidative stress. The resulting damage is the key step in the onset and progression of many disease states.
Degenerative nerve diseases relates to progressive damage to the neurons in the nervous system. Several nervous disorder includes Alzheimer's disease (AD), Parkinson's disease (PD), Dementia and so on. Several endogenous and exogenous compound are known to protect against oxidative stress and apoptosis. These endogenous and exogenous compound are helpful in management and prevention of degenerative nerve diseases.
L-Carnosine is used as protective agent for many therapies. Ginkgo Biloba extract reduces oxidative damage and stimulates cell survival. While both these compounds are known to be administrated individually for their respective mechanism of action, administration with immediate release has a limitation of multiple daily administration leading to fluctuating plasma concentrations.
Therefore, there is an urgent need for the improved controlled delivery therapy with pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract which can delivery either or both active ingredients in controlled manner.
Till date, pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one or both active ingredient are in controlled release form, are not known.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The present invention relates to pharmaceutical composition comprising L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract. The active ingredient as per present invention are used in therapeutically effective amount.
“Therapeutically effective amount” or “effective amount” refers to the amount of a pharmaceutically active agent when administered, is sufficient to affect such prevention or treatment. The therapeutically effective amount will vary depending on the disease and its severity, and the age, weight, and other conditions of the patient to be treated. The term “pharmaceutical compositions” herein refers to any composition for administration to human or animal by any route and includes but are not limited to delayed release, extended release and pulsed-release.
The term “immediate release” herein refers to any composition for administration to human or animal which releases active ingredient upon administration immediately.
The term “controlled release” herein refers to any composition for administration to human or animal which is not immediate release and includes extended release, delayed release and pulsatile release.
In an embodiment, the present invention relates to a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
In an embodiment, the present invention relates to a pharmaceutical composition comprising a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form.
In an embodiment, the present invention relates to a pharmaceutical composition consisting of a. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
In an embodiment, the present invention relates to a controlled release pharmaceutical composition comprising c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
In an embodiment, the present invention relates to a controlled release pharmaceutical composition consisting of c. therapeutically effective amount of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and d. Ginkgo Biloba extract.
In a preferred embodiment, the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
In a preferred embodiment, the present invention relates to a pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form. In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein at least one active ingredient is in controlled release form.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition is a bilayer tablet.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition comprises comprises Hydroxy Propyl Methyl cellulose as extended release polymer. In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in controlled release form and wherein said composition releases less than 90% L-Carnosine or pharmaceutically acceptable salts or derivatives thereof after 8 hours in 6.8 pH phosphate buffer.
In a preferred embodiment, the present invention relates to an oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg, wherein L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in extended release form and wherein said composition is a bilayer tablet.
In a preferred embodiment, the present invention relates to a controlled release pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
In a preferred embodiment, the present invention relates to a controlled release oral pharmaceutical comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg.
In one or more embodiments, a pharmaceutical composition as per present invention includes delayed release, extended release, pulsatile release or combination thereof.
In one or more embodiments, a pharmaceutical composition as per present invention comprises active ingredients in homogenous mixture or physically separated compartments.
In one or more embodiments, a pharmaceutical composition as per present invention comprises L-Carnosine or pharmaceutically acceptable salts or derivatives thereof are in extended release form.
In one or more embodiments, a pharmaceutical composition as per present invention includes for oral, intravenous or other routes of administration.
In one or more embodiments, a pharmaceutical composition as per present invention includes solid, liquid, semisolid or other dosage forms.
In one or more embodiments, the present invention also relates to a process for preparation of a pharmaceutical composition wherein said process comprises step of a. Preparing granules of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof with at least one controlled release excipient, b. Preparing granules of Ginkgo Biloba extract, c. Processing granules of step (a) and step (b) into bilayer tablet. In a preferred embodiments, a process as per present invention involves non aqueous solvent granulation.
L- Carnosine
Carnosine is an endogenous dipeptide, composed of b-alanine and L- histidine. Carnosine has pH-buffering, metal-ion chelation, and antioxidant capacity as well as the capacity to protect against formation of advanced glycation and lipoxidation end-products. Carnosine is found naturally mainly in the skeletal muscles, central nervous system, olfactory neurons and in the lens of the eye in some vertebrates, including humans.
It has been suggested that carnosine may be involved in the prevention and therapy of oxidative driven disorders, including neurodegenerative diseases and hypoxic-ischemic damage of CNS. Carnosine treatment has been reported to improve glucose metabolism as well as spatial recognition memory, retention and recall. It has also been reported to have pronounced neuroprotective action on Parkinson’s disease increasing efficiency of basic therapy and suppressing beta amyloid peptide toxicity in Alzheimer’s disease.
In one or more embodiments, L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in the equivalent therapeutically effective amount of L-Carnosine. In a preferred embodiment, L-Carnosine or pharmaceutically acceptable salts or derivatives thereof is in an amount equivalent to 50mg to 400mg of L-Camosine.
Ginkgo Biloba Extract
Ginkgo Biloba is the leaf extract primarily for China. It has antioxidant, anti-apoptotic, anti-ageing properties. In ancient and modem Chinese herbal pharmacopoeia, it is indicated for treatment for heart and lung complications. In US and Europe, it is used for its protective effect on neuron in de-generative dementias of the Alzheimer type. Dementia is a chronic or progressive condition characterized by impaired cognitive capacity.
Ginkgo Biloba Extract mainly contains 22.0 - 27.0% flavonoids, calculated as flavonoid glycosides and terpenoids, terpenoids consisting of bilobalide and the ginkgolides (2.6 - 3.2% bilobalide and 2.8 - 3.4% ginkgolides A, B and C). Usually administered doses of Ginkgo Biloba extract is 120-240 mg/day divided into 2 or 3 doses with meals. It has time to peak plasma concentration (Tmax) of 1 to 2 hours and shorter plasma half-life of ginkgolide A (3 to 4 hours) and B (4 to 6 hours) and bilobalide (2 to 3 hours) with primary excreted in the urine unchanged. Multiple daily doses lead to non-uniform plasma levels of its content in the body.
In one or more embodiments, Ginkgo Biloba Extract is in an amount of 20 mg to 200 mg.
Pharmaceutical Composition
L-Carnosine is the antioxidant with neuroprotective effect through involvement in endogenous pathway. Gingko biloba extract is a herbal exogenous antiapoptotic agent with directly neuroprotective effect. The present invention relates to a pharmaceutical composition comprising L-Camosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form. The present invention relates to a controlled release pharmaceutical composition comprising L- Carnosine or pharmaceutically acceptable salts or derivatives thereof, and Ginkgo Biloba extract.
The pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Carnosine in the ratio between 1:1 and 1:6. In one embodiment, the pharmaceutical composition as per present invention contains Ginkgo Biloba extract and L-Camosine in an amount of 60mg;200mg, 90mg;300mg and 120mg; 400mg.
The pharmaceutical compositions are the different type of medicinal preparation designed for the administration of targeted one or more drugs. The pharmaceutical compositions as per present invention includes immediate release, delayed release, extended release and pulsed-release. The pharmaceutical compositions can be prepared using uniform mixture of two or more drugs. In one or more embodiments, pharmaceutical composition can be prepared with one or more drugs in separate compartment within a single dosage form. The pharmaceutical compositions as per present invention can be administered by oral, intravenous or other routes of drug administration. The pharmaceutical compositions as per present invention can be solid, liquid, semisolid or any other dosage form. The pharmaceutical compositions as per present invention can be prepared as one or more drug in modified release and other drugs as immediate release in single dosage form.
The oral pharmaceutical dosage form are tablets, capsules, suspensions, powders and granules, multi-particulate dosage forms and the likes. The multicompartment dosage form are bilayer tablets, capsule-in-capsule, tablet-in capsule and any other dosage form. The pharmaceutical compositions can be formulated by any techniques known to or appreciated by a person skilled in the art
The controlled release excipients as per present invention includes enteric polymer, sustained release polymers, natural polysaccharides, wax. The representative controlled release agents are hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, polyethylene glycol, sodium alginate and so on. In an embodiment, the oral pharmaceutical composition further includes optionally any one or a combination of one or more pharmaceutically acceptable excipients, such as but not limited to carriers, diluents, fillers, disintegrants, lubricating agents, binders, colorants, pigments, stabilizers, preservatives, antioxidants and solubility enhancers.
Having described the invention with reference to the different embodiments of the invention, other embodiments will become apparent to one skilled in the art from consideration of the specifications.
The innovation is further defined by reference to the following examples. It will be apparent to those skilled in the art that many modifications, both to the composition and treatment, may be practiced without departing from the scope of this invention.
EXAMPLE - 1
Representative tablet composition of L- Camosine and Ginkgo Biloba extract
Figure imgf000012_0001
EXAMPLE - 2
Representative capsule composition of L- Carnosine and Ginkgo Biloba extract
Figure imgf000013_0001
EXAMPLE - 3
Representative capsule composition of L- Carnosine and Ginkgo Biloba extract
Figure imgf000013_0002
EXAMPLE - 4
Each film coated bilayer tablet Contains: Ginkgo biloba 60 mg (as immediate release form) and L-Camosine 200 mg (as sustained release form)
Figure imgf000013_0003
Figure imgf000014_0001
L- Carnosine (SR) Layer:
Mix L-Carnosine, Hydroxy Propyl Methyl cellulose (K4-M), Microcrystalline Cellulose (PH-101) and Dicalcium Phosphate dihydrate into the RMG.
Add the Povidone IPA binder solution slowly in to RMG to get uniform granulated mass. Sift the semi dried granules and dried granules through 20# mesh sieve and collect into a poly bag.
Sift Hydroxy Propyl Methyl cellulose (K-100), Colloidal Silicon di oxide, Croscarmellose sodium and Sodium stearyl fumarate through 40# mesh sieve and collect into a poly bag Transfer the 20# mesh sifted dried granules into the blender and add the total sifted (40 # mesh) quantity of Hydroxy Propyl Methyl cellulose (K-100), Colloidal Silicon di oxide, Croscarmellose sodium and Sodium stearyl fumarate into the blender and mix for 15min at 10 RPM.
Sift total dispensed quantity of Magnesium stearate through 40# mesh sieve and transfer into the above blender and mix for 5min at 10 RPM.
Collect the sifted dried granules in poly bags.
Ginkgo Biloba Layer:
Sift Ginkgo Biloba Extract, Microcrystalline cellulose (PH -102), Crospovidone (XL- 10) through 40# mesh sieve and collect into a poly bag and transfer the sifted dry mix part into the RMG and mix for 15min with impeller at slow speed and Chopper off.
Add the Povidone IPA binder solution slowly in to RMG to get uniform granulated mass.
Dry the above wet mass. Sift the semi dried granules and dried granules through 20# mesh sieve and collect into a poly bag.
Sift Crospovidone (XL- 10, Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate through 40# mesh sieve and collect into a poly bag Transfer the 20# mesh dried sifted granules into the blender and add the total sifted (40 # mesh) quantity of Crospovidone (XL- 10), Colloidal Silicon di oxide, Polacrilin Potassium and Sodium stearyl fumarate into the blender and mix for 15min at 10 RPM.
Sift total dispensed quantity of Magnesium stearate through 40# mesh sieve and transfer into the above blender and mix for 5min at 10 RPM.
Collect the sifted dried granules in a poly bags and labeled with product identity.
Compression and Coating
The above lubricated blend (L- Carnosine (SR) Layer and Ginkgo Biloba Layer) compressed using caplet shaped, slightly biconvex with break line on one side and plain on another side punch. The compressed tablets are coated with Insta sol. Dissolution for L-Carnosine using 6.8 pH phosphate buffer. (USP 2; Volume 900ml, 50RPM)
Figure imgf000016_0001

Claims

CLAIMS I/WE Claims
1. A pharmaceutical composition comprising a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof, and b. Ginkgo Biloba extract, wherein at least one active ingredient is in controlled release form.
2. The pharmaceutical composition according to the claim 1, wherein said composition comprises a. L-Carnosine or pharmaceutically acceptable salts or derivatives thereof in an amount equivalent to 50 mg to 400 mg of L-Carnosine, and b. Ginkgo Biloba extract in an amount of 20 mg to 200 mg
3. The pharmaceutical composition according to the claim 1, wherein said composition comprises L-Carnosine or pharmaceutically acceptable salts or derivatives thereof are in controlled release form.
4. The pharmaceutical composition according to the claim 3, wherein said controlled release form is extended release form.
5. The pharmaceutical composition according to the claim 1, wherein said composition is a bilayer tablet.
6. The pharmaceutical composition according to the claim 4, wherein said extended release form further comprises Hydroxy Propyl Methyl cellulose as extended release polymer.
7. The pharmaceutical composition according to the claim 1, wherein said composition is oral dosage form.
8. The pharmaceutical composition according to the claim 1, wherein said composition releases less than 90% L-Camosine or pharmaceutically acceptable salts or derivatives thereof after 8 hours in pH 6.8 phosphate buffer.
9. A process for preparation of a pharmaceutical composition wherein said process comprises step of a. Preparing granules of L-Carnosine or pharmaceutically acceptable salts or derivatives thereof with at least one controlled release excipient, b. Preparing granules of Ginkgo Biloba extract, c. Processing granules of step (a) and step (b) into bilayer tablet.
10. The process according to claim 1, wherein said granules are prepared using non aqueous solvent granulation.
PCT/IB2021/055647 2020-06-25 2021-06-25 A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract WO2021260636A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021027027 2020-06-25
IN202021027027 2020-06-25

Publications (1)

Publication Number Publication Date
WO2021260636A1 true WO2021260636A1 (en) 2021-12-30

Family

ID=79282177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/055647 WO2021260636A1 (en) 2020-06-25 2021-06-25 A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract

Country Status (1)

Country Link
WO (1) WO2021260636A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259150A (en) * 2008-04-22 2008-09-10 复旦大学 Sustained-release pellet of ginkgo biloba extract and its preparation
WO2012146592A1 (en) * 2011-04-27 2012-11-01 Dr. Willmar Schwabe Gmbh & Co. Kg Controlled release tablet of ginkgo biloba extract and procedure for obtaining it

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259150A (en) * 2008-04-22 2008-09-10 复旦大学 Sustained-release pellet of ginkgo biloba extract and its preparation
WO2012146592A1 (en) * 2011-04-27 2012-11-01 Dr. Willmar Schwabe Gmbh & Co. Kg Controlled release tablet of ginkgo biloba extract and procedure for obtaining it

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Kobacar tablet", SEPTALYST, 11 July 2019 (2019-07-11) *
CUI Q ET AL.: "Preparation and in vitro release of Ginkgo biloba extract sustained-release tablets", ZHONGGUO ZHONG YAO ZA ZHI, vol. 34, no. 15, 8 January 2009 (2009-01-08), pages 1910 - 13 *

Similar Documents

Publication Publication Date Title
US20220226295A1 (en) Method of treatment with tradipitant
US11318144B2 (en) Compositions and methods for treating Alzheimer's disease and Parkinson's disease
CA3183560A1 (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
JPH0635382B2 (en) Uses of fluoxetine as an anxiolytic
US20060246133A1 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
US11376267B2 (en) Drug combination for treatment of amyotrophic lateral sclerosis, preparation method and use thereof
KR20190014512A (en) Small-sized Melatonin Tablets and Manufacturing Method Thereof
AU2014326142B2 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
WO2021260636A1 (en) A pharmaceutical composition comprising l-carnosine and ginkgo biloba extract
US7867524B2 (en) Energizing formulation
RU2336076C2 (en) Peroral medical product for offset of magnesium deficiency in organism
WO2017029225A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
JP2003095981A (en) Medicine composition
US11179377B2 (en) Pharmaceutical compositions and uses thereof
US20130143912A1 (en) Sublingual zolpidem formulations
US20210052608A1 (en) Methods of treating bacterial infections with minocycline
US20240082176A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup and tablets
WO2023240092A1 (en) Ebselen containing oral dosage forms
KR20170000907A (en) Pharmaceutical composition comprising the isopropanol extract of artemisia
KR20150063040A (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
JP5822420B2 (en) Pharmaceutical composition
KR20110008773A (en) Sustained release mini-tablet containing doxophylline and preparation method thereof
US20040192706A1 (en) Method and compositions for treating anxiety
JPH07188004A (en) Medicine for cold

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21827995

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21827995

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 21827995

Country of ref document: EP

Kind code of ref document: A1